Logo image of AARD

AARDVARK THERAPEUTICS INC (AARD) Stock Fundamental Analysis

NASDAQ:AARD - Nasdaq - US0029421007 - Common Stock - Currency: USD

10.44  +0.14 (+1.36%)

After market: 10.96 +0.52 (+4.98%)

Fundamental Rating

3

Overall AARD gets a fundamental rating of 3 out of 10. We evaluated AARD against 197 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for AARD as it has an excellent financial health rating, but there are worries on the profitability. AARD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AARD has reported negative net income.
AARD Yearly Net Income VS EBIT VS OCF VS FCFAARD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

AARD has a Return On Assets of -24.59%. This is comparable to the rest of the industry: AARD outperforms 57.87% of its industry peers.
With a decent Return On Equity value of -25.55%, AARD is doing good in the industry, outperforming 67.01% of the companies in the same industry.
Industry RankSector Rank
ROA -24.59%
ROE -25.55%
ROIC N/A
ROA(3y)-58.64%
ROA(5y)N/A
ROE(3y)-64.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AARD Yearly ROA, ROE, ROICAARD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AARD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AARD Yearly Profit, Operating, Gross MarginsAARD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

AARD has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for AARD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AARD Yearly Shares OutstandingAARD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
AARD Yearly Total Debt VS Total AssetsAARD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 41.90 indicates that AARD is not in any danger for bankruptcy at the moment.
AARD has a better Altman-Z score (41.90) than 95.94% of its industry peers.
AARD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 41.9
ROIC/WACCN/A
WACCN/A
AARD Yearly LT Debt VS Equity VS FCFAARD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

AARD has a Current Ratio of 31.65. This indicates that AARD is financially healthy and has no problem in meeting its short term obligations.
AARD has a Current ratio of 31.65. This is amongst the best in the industry. AARD outperforms 98.48% of its industry peers.
A Quick Ratio of 31.65 indicates that AARD has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 31.65, AARD belongs to the best of the industry, outperforming 98.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 31.65
Quick Ratio 31.65
AARD Yearly Current Assets VS Current LiabilitesAARD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for AARD have decreased strongly by -185.61% in the last year.
EPS 1Y (TTM)-185.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-330.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AARD will show a very negative growth in Earnings Per Share. The EPS will decrease by -44.82% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-173.33%
EPS Next 2Y-62.58%
EPS Next 3Y-44.82%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AARD Yearly Revenue VS EstimatesAARD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 5M 10M 15M 20M
AARD Yearly EPS VS EstimatesAARD Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AARD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AARD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AARD Price Earnings VS Forward Price EarningsAARD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AARD Per share dataAARD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

AARD's earnings are expected to decrease with -44.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.58%
EPS Next 3Y-44.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AARD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AARDVARK THERAPEUTICS INC

NASDAQ:AARD (5/30/2025, 8:00:00 PM)

After market: 10.96 +0.52 (+4.98%)

10.44

+0.14 (+1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)N/A N/A
Inst Owners24.9%
Inst Owner ChangeN/A
Ins Owners31.14%
Ins Owner Change4.69%
Market Cap226.55M
Analysts84
Price Target32.13 (207.76%)
Short Float %1.87%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.81%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.81
P/tB 2.81
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-2.63
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS3.71
TBVpS3.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.59%
ROE -25.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.64%
ROA(5y)N/A
ROE(3y)-64.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 31.65
Quick Ratio 31.65
Altman-Z 41.9
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-185.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-330.29%
EPS Next Y-173.33%
EPS Next 2Y-62.58%
EPS Next 3Y-44.82%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-207.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-187.58%
EBIT Next 3Y-64.19%
EBIT Next 5YN/A
FCF growth 1Y-212.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.56%
OCF growth 3YN/A
OCF growth 5YN/A